A Study of RAY1225 in Participants With Type 2 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions

T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

Peking University People's Hospital, Beijingcun

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT06254274 - A Study of RAY1225 in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter